title: Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
abstract: Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation.
authors.affiliation: Division of Hemato-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.
authors.forename: Guan-Min
authors.initials: GM
authors.lastname: Lai
authors.forename: Sheng-Lei
authors.initials: SL
authors.lastname: Yan
authors.forename: Cheng-Shyong
authors.initials: CS
authors.lastname: Chang
authors.forename: Chien-Yu
authors.initials: CY
authors.lastname: Tsai
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib
keywords: Chronic myeloid leukemia; Hepatitis B virus; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor